Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
3,351 results
  • Can Ph-like ALL be effectively targeted? [Review]
    Best Pract Res Clin Haematol 2019; 32(4):101096Maese L, Raetz EA
  • Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subset of B-cell ALL with a spectrum of underlying genetic alterations that activate kinase or cytokine receptor signaling. Ph-like ALL occurs at all ages but is most common in adolescents and young adults and is postulated to be a factor in the inferior outcomes in this age group. Ph-like ALL confers a poor pr…
  • Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach? [Review]
    Best Pract Res Clin Haematol 2019; 32(4):101102Derman BA, Larson RA
  • Recent advances in remission induction treatment strategies for acute myeloid leukemia (AML) have improved the rates of complete remission (CR) and overall survival (OS), owing to a concerted effort to tailor therapies toward specific AML subtypes. However, without effective post-remission therapy, most patients will relapse. The extent to which post-remission therapies is individualized in the c…
  • Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia. [Review]
    Curr Hematol Malig Rep 2019Rabian F, Lengline E, Rea D
  • Treatment goals and ambitions have even been upwardly revised since demonstration was made that under certain conditions, treatment-free remission was possible. Herein, we will discuss on how to try tailoring treatment choices to the unique characteristics of each patient.
  • Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. [Review]
    J Eur Acad Dermatol Venereol 2019Di Nardo L, Pellegrini C, … Peris K
  • Cutaneous squamous cell carcinoma (cSCC) represents 20% of all skin cancers. Although primary cSCCs can be successfully treated with surgery, a subset of highly aggressive lesions may progress to advanced disease, representing a public health care problem with significant cancer-related morbidity and mortality. A complex network of genes (TP53, CDKN2A, NOTCH1 and NOTCH2, EGFR and TERT) and molecu…
  • MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma. [Journal Article]
    Oncogene 2019Castillo L, Young AIJ, … Oakes SR
  • Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. It is phenotypically heterogeneous with a highly unstable genome and provides few common therapeutic targets. We found that MCL1, Cofilin1 (CFL1) and SRC mRNA were highly expressed by a wide range of these cancers, suggesting that a strategy of dual MCL-1 and SRC inhibition might be efficacious for many patients. I…
New Search Next